PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors
PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
Provided By GlobeNewswire – Last update: